Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) shares dropped 5.8% on Wednesday . The company traded as low as $7.52 and last traded at $7.61, with a volume of 130,591 shares changing hands. The stock had previously closed at $8.08.

ADAP has been the subject of a number of research analyst reports. Zacks Investment Research lowered Adaptimmune Therapeutics PLC – from a “buy” rating to a “hold” rating in a research report on Monday, August 1st. Leerink Swann restated a “buy” rating on shares of Adaptimmune Therapeutics PLC – in a research report on Sunday, April 24th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $15.94.

The company’s 50-day moving average price is $8.26 and its 200 day moving average price is $8.65. The firm’s market capitalization is $538.67 million.

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) last issued its quarterly earnings data on Monday, August 8th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.16. On average, analysts expect that Adaptimmune Therapeutics PLC – will post ($1.17) earnings per share for the current year.

In other news, Director Charles Elliott Sigal acquired 45,000 shares of the firm’s stock in a transaction on Wednesday, May 18th. The stock was acquired at an average price of $1.53 per share, for a total transaction of $68,850.00. Following the completion of the transaction, the director now owns 52,938 shares in the company, valued at approximately $80,995.14. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Orbimed Advisors Llc acquired 1,712,400 shares of the firm’s stock in a transaction on Tuesday, May 24th. The stock was purchased at an average price of $10.42 per share, with a total value of $17,843,208.00. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in Adaptimmune Therapeutics PLC – stock. Jennison Associates LLC boosted its position in Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) by 0.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 486,948 shares of the company’s stock after buying an additional 1,547 shares during the period. Jennison Associates LLC owned approximately 0.69% of Adaptimmune Therapeutics PLC – worth $5,873,000 as of its most recent SEC filing.

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.